CRISPR Therapeutics' Julianne Bruno, M.B.A., Promoted To COO, Effective May 23, 2024
CRISPR Therapeutics' Julianne Bruno, M.B.A., Promoted To COO, Effective May 23, 2024
-Naimish Patel, M.D., appointed to Chief Medical Officer-
-医学博士奈米什·帕特尔被任命为首席医疗官-
-Julianne Bruno, M.B.A., promoted to Chief Operating Officer-
-工商管理硕士朱丽安·布鲁诺晋升为首席运营官-
ZUG, Switzerland and BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Naimish Patel, M.D., as Chief Medical Officer, effective May 28, 2024. Dr. Patel is an experienced drug developer who has worked across a wide range of disease areas, including his most recent leadership role as the Global Development Therapeutic Area Head of Immunology and Inflammation at Sanofi. In addition, the Company also announced the promotion of Julianne Bruno, M.B.A., to Chief Operating Officer, effective as of May 23, 2024. She currently serves as the Company's Senior Vice President and Head of Programs & Portfolio Management.
瑞士楚格和波士顿，2024年5月23日（环球新闻专线）——专注于为严重疾病开发变革性基因药物的生物制药公司CRISPR Therapeutics（纳斯达克股票代码：CRSP）今天宣布任命医学博士奈米什·帕特尔为首席医学官，自2024年5月28日起生效。帕特尔博士是一位经验丰富的药物开发人员，曾在广泛的疾病领域工作，包括他最近担任赛诺菲全球开发治疗领域免疫学和炎症负责人的领导职务。此外，该公司还宣布将工商管理硕士朱丽安·布鲁诺晋升为首席运营官，自2024年5月23日起生效。她目前担任公司高级副总裁兼项目与投资组合管理主管。